Loading
Life sciences · Journal article
Acs Nano · September 28, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Tumor chemoresistance, driven by mechanisms such as drug efflux, DNA repair, apoptosis inactivation, immunosuppressive microenvironments, and the maintenance of cancer stem cell (CSC) stemness, remains a major obstacle to effective chemotherapy and patient prognosis. Engineered nanoplatforms offer multifaceted strategies to overcome these barriers, including passive targeting, ligand-mediated active targeting, and membrane-mimetic camouflage for enhanced tumor accumulation. Stimuli-responsive and prodrug-based systems exploit tumor microenvironmental features, such as low pH, high glutathione, enzyme overexpression, and redox gradients, to achieve precise spatiotemporal drug release while avoiding efflux and inactivation. Codelivery of chemotherapeutics with sensitizers, immunotherapeutic agents, gene therapeutics, or physical stimuli enables synergistic intervention across multiple resistance pathways. Critically, CSC-targeted nanoplatforms selectively eliminate the root causes of tumor relapse and metastasis. By integrating targeted delivery, controlled release, multidrug synergy, and CSC elimination, nanotechnology platforms transform the management of chemoresistance from passive mitigation toward proactive prevention, offering a promising foundation for clinical translation and personalized cancer therapy.